Kaleido Financial Statements From 2010 to 2021

KLDO -  USA Stock  

USD 5.83  0.38  6.97%

Kaleido Biosciences financial statements provide useful quarterly and yearly information to potential Kaleido Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Kaleido Biosciences financial statements helps investors assess Kaleido Biosciences' valuation, profitability, and current liquidity needs.
We have found fifty-three available fundamental ratios for Kaleido Biosciences, which can be analyzed and compared to other ratios and to its peers in the industry. We recommend to check Kaleido Biosciences' last-minute fundamental drivers against the all of the trends between 2010 and 2021.
Kaleido Biosciences Invested Capital is quite stable at the moment as compared to the past year. The company's current value of Invested Capital is estimated at 16.41 Million. Tangible Asset Value is expected to rise to about 68.5 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (83.1 M).

Search Financial Statements 

 
Refresh
Check Kaleido Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kaleido main balance sheet or income statement drivers, such as Gross Profit of 872.4 K, Interest Expense of 2.2 M or Operating Expenses of 78.8 M, as well as many exotic indicators such as Asset Turnover of 0.0125, Book Value per Share of 0.66 or Current Ratio of 4.08. Kaleido financial statements analysis is a perfect complement when working with Kaleido Biosciences Valuation or Volatility modules. It can also supplement various Kaleido Biosciences Technical models. Please see the analysis of Kaleido Biosciences Correlation against competitors.

Kaleido Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets68.5 M59.3 M45.1 M
Increasing
Slightly volatile
Cash and Equivalents58.6 M48.4 M40.7 M
Increasing
Slightly volatile
Property Plant and Equipment Net7.6 M8.5 M3.6 M
Increasing
Slightly volatile
Trade and Non Trade Receivables40.3 K40.5 K44.2 K
Decreasing
Slightly volatile
Trade and Non Trade Payables4.5 M5.4 M1.9 M
Increasing
Slightly volatile
Total Liabilities38.2 M38.8 M26.2 M
Increasing
Slightly volatile
Shareholders Equity22.1 M20.5 M(29.5 M)
Increasing
Slightly volatile
Current Assets58.5 M48.7 M40.4 M
Increasing
Slightly volatile
Assets Non Current10.1 M10.6 M4.7 M
Increasing
Slightly volatile
Current Liabilities14.9 M16.7 MM
Increasing
Slightly volatile
Liabilities Non Current23.3 M22.2 M19.2 M
Increasing
Slightly volatile
Total Debt21.3 M21 M16.3 M
Increasing
Slightly volatile
Debt Current2.4 M2.4 M2.6 M
Decreasing
Slightly volatile
Debt Non Current19.6 M18.4 M16 M
Increasing
Slightly volatile
Shareholders Equity USD22.1 M20.5 M(29.5 M)
Increasing
Slightly volatile
Cash and Equivalents USD58.6 M48.4 M40.7 M
Increasing
Slightly volatile
Total Debt USD21.3 M21 M16.3 M
Increasing
Slightly volatile

Kaleido Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues872.4 K877.5 K958.3 K
Decreasing
Slightly volatile
Selling General and Administrative Expense22.8 M23.9 M11.3 M
Increasing
Slightly volatile
Research and Development Expense56 M56 M32.2 M
Increasing
Slightly volatile
Operating Expenses78.8 M79.8 M43.5 M
Increasing
Slightly volatile
Interest Expense2.2 M2.8 M874.5 K
Increasing
Slightly volatile
Weighted Average Shares27.6 M33.5 M10.6 M
Increasing
Slightly volatile
Weighted Average Shares Diluted27.6 M33.5 M10.6 M
Increasing
Slightly volatile
Revenues USD872.4 K877.5 K958.3 K
Decreasing
Slightly volatile
Gross Profit872.4 K877.5 K958.3 K
Decreasing
Slightly volatile

Kaleido Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing49 M40.4 M55.1 M
Increasing
Stable
Issuance Repayment of Debt Securities (150.9 K)(147 K)7.1 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares37.6 M40.5 M14.2 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(25.8 M)(25.1 M)16.7 M
Decreasing
Slightly volatile
Share Based Compensation11.1 M12.7 M3.8 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion1.6 M1.8 M669.6 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(2.37)(2.31)0.1785
Decreasing
Slightly volatile
Gross Margin0.890.90.9829
Decreasing
Slightly volatile
Asset Turnover0.01250.01260.0138
Decreasing
Slightly volatile
Sales per Share0.02590.02610.0285
Decreasing
Slightly volatile
Price to Sales Ratio279281307
Decreasing
Slightly volatile
Price to Book Value13.9215.9765.0642
Increasing
Slightly volatile
Debt to Equity Ratio2.041.8950.0261
Increasing
Slightly volatile
Current Ratio4.082.9256.6733
Decreasing
Slightly volatile
Book Value per Share0.660.613(7.8202)
Increasing
Slightly volatile
Tangible Assets Book Value per Share1.821.7746.5446
Decreasing
Stable

Kaleido Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization310.8 M327.4 M178.9 M
Increasing
Slightly volatile
Enterprise Value261.7 M291.6 M114.7 M
Increasing
Slightly volatile
Invested Capital16.4 M15.3 M13.8 M
Increasing
Slightly volatile
Average Equity38.1 M35.3 M(40 M)
Increasing
Slightly volatile
Average Assets82.7 M71.6 M65 M
Increasing
Slightly volatile
Invested Capital Average20 M20.9 M13.4 M
Increasing
Slightly volatile
Tangible Asset Value68.5 M59.3 M45.1 M
Increasing
Slightly volatile
Working Capital43.6 M32.1 M33.4 M
Increasing
Slightly volatile

Kaleido Fundamental Market Drivers

Short Percent Of Float16.12%
Forward Price Earnings-2.43
Shares Short Prior Month3.25M
Average Daily Volume Last 10 Day124.6k
Average Daily Volume In Three Month250.4k
Date Short Interest28th of May 2021
Fifty Day Average5.94
Two Hundred Day Average7.16

Kaleido Upcoming Events

Upcoming Quarterly Report1st of November 2021
Next Earnings Report2nd of March 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End2nd of March 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

About Kaleido Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kaleido Biosciences income statement, its balance sheet, and the statement of cash flows. Kaleido Biosciences investors use historical funamental indicators, such as Kaleido Biosciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kaleido Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kaleido Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Revenues877.5 K872.4 K
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now

   

Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kaleido Biosciences Correlation against competitors. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.